York Capital Management Global Advisors’s Bristol-Myers Squibb BMY Stock Holding History

York Capital Management Global Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,233,754	Closed	-$78M	–	72
2018 Q1	$78M	Buy	+1,233,754	New	+$79.4M	1.75%	12

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

York Capital Management Global Advisors's BMY Position: Q2 2018 in Review

York Capital Management Global Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2018, closing a stake of 1,233,754 shares — an estimated $78M sold.

York Capital Management Global Advisors first reported a position in BMY in Q1 2018 and held it in 1 quarter. The position peaked at $78M in Q1 2018. 1,692 funds tracked by Wall St. Rank hold BMY as of Q2 2018.

York Capital Management Global Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2018 after selling out during the quarter.
York Capital Management Global Advisors sold 1,233,754 Bristol-Myers Squibb shares in Q2 2018, an estimated $78M.
York Capital Management Global Advisors first reported a position in Bristol-Myers Squibb in Q1 2018 and held it in 1 quarter.
York Capital Management Global Advisors's Bristol-Myers Squibb position peaked at $78M in Q1 2018.
1,692 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2018.

Based on York Capital Management Global Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.